Table 4.
Case #2 selected results of the panel-pharmacogenotyping and phenotype interpretation.
| Gene | Variant (Also Tested Variants in Gene Locus) |
Genotype | Predicted Phenotype |
|---|---|---|---|
| CYP1A2 | rs762551 g.75041917C > A (in *1F) (rs2069514) |
C/A | Increased inducibility |
| CYP2B6 | (rs8192709, rs28399499, rs3745274) | WT 4, *1 | Normal function (NM 1) |
| CYP2C19 | rs4244285 c.681G > A (in *2) (rs4986893, rs12248560, rs28399504) |
G/A | Decreased function (IM 2) |
| CYP2D6 | rs3892097 c.506-1G > A (in *4) | G/A C/T |
Decreased function (IM 2) |
| rs1065852 c.100C > T (in *4) (CNV, rs35742686, rs5030655, rs5030867, rs5030865, rs5030656, rs201377835, rs28371706, rs59421388, rs28371725) | |||
| CYP3A4 | (rs2242480, rs2740574) | WT 4, *1 | Substance-specific function |
| CYP3A5 | rs776746 c.219-237A > G (in *3) | G/G | No function (PM 3) |
| ABCB1 | rs2032583 c.2685+49T > C (rs1045642, rs1128503, rs2032582) |
T/T | Substance-specific function |
1 NM: normal metabolizer; 2 IM: intermediate metabolizer; 3 PM: poor metabolizer; 4 WT: wild type.